Compass Pathways (NASDAQ:CMPS – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15, FiscalAI reports.
Here are the key takeaways from Compass Pathways’ conference call:
- COMPASS said it has now reported positive Phase III data from both pivotal TRD studies, with COMP360 showing rapid onset and durable efficacy across a program of more than 1,000 patients.
- The company reiterated it is launch-ready by year-end and has begun its rolling NDA submission, with the final expected dataset from COMP006 Part B due in early Q3.
- Management highlighted the Commissioner’s National Priority Voucher as a potential acceleration tool, and said it is working closely with FDA and DEA to compress review and rescheduling timelines as much as possible.
- COMPASS said its commercial readiness is advancing quickly, including a growing sales organization, payer engagement, and state/federal access planning; it also expects the existing CPT III reimbursement codes to support provider monitoring costs.
- Beyond TRD, the company is moving ahead with a late-stage PTSD program, which it plans to run as a single registration trial, while also exploring broader future opportunities in other neuropsychiatric disorders.
Compass Pathways Stock Performance
Shares of NASDAQ CMPS traded down $0.09 during midday trading on Thursday, reaching $10.87. The company’s stock had a trading volume of 2,849,049 shares, compared to its average volume of 3,540,388. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $11.28. The firm has a 50 day moving average price of $7.09 and a 200-day moving average price of $6.69. The stock has a market capitalization of $1.40 billion, a P/E ratio of -3.52 and a beta of 2.39. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.77 and a quick ratio of 0.77.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on CMPS
Hedge Funds Weigh In On Compass Pathways
A number of hedge funds and other institutional investors have recently modified their holdings of CMPS. Squarepoint Ops LLC bought a new stake in shares of Compass Pathways in the 4th quarter worth approximately $131,000. The Manufacturers Life Insurance Company bought a new stake in Compass Pathways during the 4th quarter valued at $96,000. Conservest Capital Advisors Inc. raised its holdings in Compass Pathways by 24.6% during the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after acquiring an additional 5,000 shares during the period. Brooklyn Investment Group bought a new position in Compass Pathways in the 4th quarter worth about $134,000. Finally, HighTower Advisors LLC increased its position in shares of Compass Pathways by 172.8% during the fourth quarter. HighTower Advisors LLC now owns 31,491 shares of the company’s stock valued at $217,000 after buying an additional 19,949 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.
Key Headlines Impacting Compass Pathways
Here are the key news stories impacting Compass Pathways this week:
- Positive Sentiment: Compass Pathways reported first-quarter EPS of -$0.30, beating Wall Street estimates and suggesting better-than-expected operating performance. Earnings report and conference call
- Positive Sentiment: Management said regulatory progress continued for COMP360 in treatment-resistant depression, including an accelerated FDA review path, which is a key catalyst for the stock. Compass Pathways shares rise on Q1 results, accelerated FDA review
- Positive Sentiment: BTIG reaffirmed its Buy rating and raised its price target to $14, signaling continued analyst confidence in upside from current levels. BTIG rating update
- Neutral Sentiment: Multiple transcript and earnings-call recaps circulated after the release, reinforcing investor attention but not adding materially new information beyond the earnings update. Q1 2026 earnings call transcript
Compass Pathways Company Profile
Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.
Featured Stories
- Five stocks we like better than Compass Pathways
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
- The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector Gains
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
